

ASX Release

SUDA LTD'S MEDICAL SUPPLIES SUBSIDIARY ACHIEVES RECORD FIRST QUARTER RESULTS

PERTH, AUSTRALIA - 18 October 2013: Suda Ltd (ASX: SUD) today announced that its fully owned subsidiary, Westcoast Surgical and Medical Supplies Pty Ltd (Westcoast), has reported its strongest quarter to date. Revenues increased by over 200% to \$3.3 million in the three months to 30 September 2013 when compared to the prior comparable period (PCP). The net profit for the quarter was \$720,000 compared to a loss in the PCP.

Westcoast is a sales and logistics operation for medical devices and consumables, based in Western Australia. In August 2013, Westcoast successfully secured preferred supplier status for an organisation funded by the Australian Federal Government. Revenue from this new contract has played a significant part in the jump in Westcoast's sales. As a result, Westcoast is on track to make a significant cash flow contribution to the financial sustainability of Suda Ltd in the second quarter.

Commenting on Westcoast's results, Mr Stephen Carter, Chief Executive Officer of Suda Ltd, said: "I am delighted by Westcoast's first quarter financial results. The comparable revenue growth of more than 200% is ahead of our internal expectations. Clearly the new contract has made a valuable contribution to Westcoast's performance. Although revenues from this source may have seasonal variation, we believe that Westcoast has entered a new era in its operations. Naturally I welcome the positive affect that Westcoast's cash flow will have on supporting our core drug delivery activities."



Further information:
STEPHEN CARTER
EXECUTIVE CHAIRMAN
SUDA LTD
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

Suda Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. Suda's most advanced product is a novel sub-lingual treatment, ArTiMist™, for severe malaria in children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other development stage products include oral sprays for the treatment of migraine headache, erectile dysfunction and chemotherapy-induced nausea and vomiting.

About WESTCOAST

Westcoast Surgical and Medical Supplies Pty Ltd is a fully owned subsidiary, which provides medical supplies to West Australian leading hospitals, aged care facilities, pharmacies, mining companies and other healthcare providers.